Novo Nordisk Files Liraglutide For Regulatory Approval For Obesity

(RTTNews) - Insulin maker Novo Nordisk A/S (NVO), Friday announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities. The firm filed a New Drug Application with the FDA, and a Marketing Authorisation Application with the European Medicines Agency.

Novo Nordisk which operates in two units, Diabetes Care and Biopharmaceuticals, engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark.